Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Not yet recruiting1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (83.3%)
Phase 41 (16.7%)

Trials by Status

not_yet_recruiting117%
active_not_recruiting117%
terminated117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_4

INSIGHT-IBD Pragmatic Study

NCT07686757
active_not_recruitingphase_1

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

NCT02483312
completedphase_1

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

NCT01266616
completedphase_1

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

NCT00528489
completedphase_1

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

NCT00004070
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07686757Phase 4

INSIGHT-IBD Pragmatic Study

Not Yet Recruiting
NCT02483312Phase 1

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Active Not Recruiting
NCT01266616Phase 1

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Completed
NCT00528489Phase 1

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

Completed
NCT00004070Phase 1

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Completed
NCT00057486Phase 1

Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6